MAFLD and MASH
NAFLD & NASH: Epidemiology & Burden, Risk Factors and Pathophysiology
- NAFLD & NASH: Introduction & Disease Burden
- Current Gaps in NASH Awareness
- NAFLD & NASH: Epidemiology & Risk Factors
- Pathophysiology, Disease Progression & Complications
- The Role of Insulin Resistance in NASH
- Epidemiology & Risk Factors: A Deeper Dive
NASH: Screening, Diagnosis, and Current Treatment Options
- NASH: Diagnosis & Risk Stratification
- Emerging Non-Invasive Diagnostic Algorithms
- Management of NASH: Lifestyle Modifications
- Overview of Guidelines, Current, and Select Emerging Treatment Options
NAFLD & NASH Diagnosis: A Deeper Dive
- Diagnosis of NAFLD: From Invasive to Non-Invasive: An Overview
- NAFLD and T2DM
- Diagnosis of Steatosis and Fibrosis in NAFLD/NASH
- Diagnosis and Management of NAFLD/NASH: A 2022 Update
- Emerging Biomarkers and Diagnostic Tools
Current Treatments for NASH: A Deeper Dive
- Current Treatments for NASH: An Introduction
- Role of Lifestyle Modifications in NASH Resolution
- Role of GLP-1 RAs and SGLT-2 Inhibitors in NASH Resolution
- Role of Pioglitazone in NASH Resolution
Future Treatments for NASH
- New Targets and Treatments for NASH
- Novel GLP-1 RAs for NASH
- Potential Role of FGF-19, FGF-21, and Thyroid Hormone Receptor Beta Selective Agonists in NASH
- Potential Role of FXR Agonists in NASH
- Summary of Novel Agents for the Treatment of NASH
Additional Information
Available Credit
- 3.75 ABIM MOC and AMA PRA Category 1 Credit™
- 3.75 ACPE Pharmacy
- 3.75 AMA PRA Category 1 Credit™
- 3.75 ANCC
- 3.75 CDE
- 3.75 Participation